On July 9, 2026 Neo7Bioscience, Inc., a leader in precision molecular solutions and AI-driven personalized peptide design, reported its innovative precision signal interception strategy as a paradigm shift in addressing the challenges of pancreatic cancer. This advancement directly responds to the limitations observed in recent targeted therapies, such as Daraxonrasib, while demonstrating superior patient outcomes through individualized, adaptive interventions.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pancreatic cancer continues to present significant clinical challenges, with a five-year survival rate of approximately 13% in 2026. While Daraxonrasib, prominently featured at the ASCO (Free ASCO Whitepaper) convention, achieved notable extensions in median progression-free survival (7.2 months versus 3.6 months with chemotherapy) and overall survival (13.2 months versus 6.7 months) in the Phase 3 RASolute 302 trial, these gains remain constrained. Tumors frequently develop resistance within months, accompanied by substantial toxicity, including Grade 3 or higher adverse events in over 61% of patients. Such therapies function primarily as temporary brakes on isolated signaling pathways, failing to address the dynamic, multi-pathway adaptability of individual tumors.
In contrast, Neo7Bioscience’s platform employs comprehensive multi-omic profiling—including ctDNA, RNA sequencing, whole-exome sequencing, urine proteomics, and fragmentomics—to construct a real-time map of active signals across all 15 Hallmarks of Cancer. Personalized therapeutic peptides are then designed via the company’s Individualized Tumor-Immune Peptide Editing Selection (ITI-PES) technology. These peptides are HLA-genotype matched for optimal immune recognition and operate through a coordinated five-phase process: Surveillance, Induction, Augmentation, Editing Effect, and Adaptation. This enables precise interception of dysregulated signals, protein-protein interactions, and escape mechanisms, with ongoing revisions informed by variant allele frequency (VAF) monitoring to counter emerging resistance, including in cancer stem cells.
Clinical Case Highlights
Two representative cases underscore the efficacy of this approach:
In a patient with Ampulla of Vater Adenocarcinoma complicated by COVID spike-related issues, 13 high-confidence personalized peptides, including designs targeting resistant EGFR/KRAS signaling and spike mitigation, facilitated transition from chemotherapy to solo peptide therapy. This resulted in tumor clearance in key areas, stability elsewhere, and sustained quality of life improvements, with adaptive designs addressing cancer stem cell signals.
A patient with Pancreatic Ductal Adenocarcinoma achieved tumor clearance and dramatic quality-of-life gains after switching to personalized peptide therapy, supported by peptides with cell- and tumor-penetrating motifs targeting key drivers such as TUBB, CDH1, MET, and others. Ongoing surveillance ensures readiness for resistance interception.
"Neo7Bioscience’s precision signal interception represents a fundamental evolution beyond population-level suppression," said Dr. John A. Catanzaro, NMD, PhD, CEO and Co-Founder of Neo7Bioscience. "By mapping and intercepting the unique, evolving signaling networks of each patient’s tumor, we deliver individualized, multi-pathway control with markedly improved tolerability and the capacity for long-term adaptation—outcomes that move decisively past the median limitations and resistance ceilings of current options."
This individualized strategy aligns with Neo7Bioscience’s PBIMA (Precision-Based ImmunoMolecular Augmentation) platform, which integrates multi-omics, hybrid intelligence, and patient-specific peptide design to target complex diseases including cancer.
(Press release, Neo7Bioscience, JUL 9, 2026, View Source [SID1234669132])